ClinicalTrials.gg
RecruitingNCT07410598Updated Jul 6, 2026

Safety and Tolerability of Patterned Stimulation for DBS in the Home Setting

An interventional study of Biphasic deep brain stimulation and Conventional deep brain stimulation in Parkinson Disease and Deep Brain Stimulation, sponsored by University of Florida. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by University of Florida · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Parkinson Disease by University of Florida — 5 open to participants now, 6 under way, none of them phase 3. Parkinson Disease · University of Florida.

Planned enrollment
8th of 33
60 · median 35
Started
2026
with 2 others
No phase
25 of 41
5 open now
Registered
40th of 41
by date

Among the 41 studies in Parkinson Disease by University of Florida, this one is the 8th largest by planned enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2026, is one of 25 with no phase, and was the 40th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

5 of the 41 studies in Parkinson Disease by University of Florida are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Parkinson Disease by University of Florida, or all of them as a file.
02

Study summary

The primary objective of the proposed pilot study is to assess the safety and tolerability of active patterned Deep Brain Stimulation (pDBS) when administered in a home setting for patients with Parkinson's disease (PD) who have had stable bilateral Subthalamic Nucleus (STN) and Globus Pallidus internus (GPi) DBS.

Read the detailed description

This pilot study will investigate the safety, tolerability, and feasibility of three distinct patterned Deep Brain Stimulation (pDBS) paradigms delivered in a home setting using the Boston Scientific Chronos Research Engine. The three stimulation patterns under evaluation are:

  1. Biphasic DBS (bDBS)
  2. Nocturnal Theta Burst Stimulation (tDBS)
  3. Region-Specific Frequency Alternation (fDBS).

Sixty patients with Parkinson's Disease (PD), each with stable bilateral Subthalamic Nucleus (STN) and Globus Pallidus internus (GPi) DBS for at least six months, will be enrolled and assigned to one of the three parallel study arms. At the baseline visit, each participant will be programmed with two stimulation settings: one replicating their chronic best clinical setting, and a second incorporating the assigned patterned stimulation.

For participants in the bDBS arm, the second setting will mirror their clinical setting but use a biphasic waveform to ensure charge balancing. In the tDBS arm, the second setting will deliver theta burst stimulation-six bursts per second at the therapeutic frequency-during nighttime hours, using the internal IPG clock to align with the participant's typical sleep schedule. For those in the fDBS arm, the second setting will apply high-frequency stimulation to dorsal contacts (Levels 3 or 4) and low-frequency stimulation (30-60 Hz) to ventral contacts (Levels 1 or 2), while maintaining all other clinical parameters.

Participants will be blinded to the identity of the two settings and will be able to switch between them using their patient programmer. The study will follow a randomized, blinded, two-period crossover design over a total duration of four weeks. During the first two weeks, participants will use one of the two programmed settings. At the end of this period, a telemedicine visit will be conducted to collect quality of life (QoL) questionnaires, related surveys, and a video-based modified MDS-UPDRS assessment. Participants will then switch to the alternate setting for the remaining two weeks. At the conclusion of the study, participants will return for an in-person research visit to complete the same assessments for the second setting. This design allows for within-subject comparison of conventional DBS and patterned DBS in a real-world, home-based environment, and will generate critical data to inform the design of a future large-scale trial.

03

Conditions studied

  • Parkinson Disease
  • Deep Brain Stimulation

Browse trials for

Keywords

  • Parkinson disease
  • PD
  • DBS
  • deep brain stimulation
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Bilateral STN or GPi DBS with Boston Scientific Vercise Genus DBS System
  • Diagnosis of Parkinson's disease as confirmed by a movement disorders fellowship trained neurologist
  • Chronic stable DBS therapy, defined as having DBS therapy for at least 6 months

Exclusion criteria

Exclusion Criteria:

  • History of previous neurosurgical intervention aside from DBS
  • Diagnosis of dementia (whether primary or related to Parkinson's disease)
  • A diagnosis of atypical parkinsonism or secondary parkinsonism at any time after DBS implantation
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Biphasic DBS (bDBS)

    For participants in the bDBS arm, the second setting will mirror their clinical setting but use a biphasic waveform to ensure charge balancing.

    Device: Biphasic deep brain stimulation · Device: Conventional deep brain stimulation

  • Experimental
    Nocturnal Theta Burst Stimulation (tDBS)

    In the tDBS arm, the second setting will deliver theta burst stimulation-six bursts per second at the therapeutic frequency-during nighttime hours, using the internal IPG clock to align with the participant's typical sleep schedule

    Device: Conventional deep brain stimulation · Device: Theta burst deep brain stimulation

  • Experimental
    Region-Specific Frequency Alternation (fDBS)

    For those in the fDBS arm, the second setting will apply high-frequency stimulation to dorsal contacts (Levels 3 or 4) and low-frequency stimulation (30-60 Hz) to ventral contacts (Levels 1 or 2), while maintaining all other clinical parameters.

    Device: Conventional deep brain stimulation · Device: Multi frequency deep brain stimulation

Interventions

  • DeviceBiphasic deep brain stimulation

    Deep brain stimulation using active recharge biphasic waveforms consisting of an equal anodic and cathodic pulse immediately delivered sequentially

  • DeviceConventional deep brain stimulation

    Conventional deep brain stimulation programming that is currently FDA approved

  • DeviceTheta burst deep brain stimulation

    Deep brain stimulation using a conventional waveform but timed such that in the evening hours (based on device clock) the device will adjust stimulation to bursts of conventional stimulation at 6 per second

  • DeviceMulti frequency deep brain stimulation

    Deep brain stimulation using conventional waveforms but simultaneously delivering high frequency stimulation on the dorsal contacts of the DBS lead and low frequency stimulation on the ventral contacts of the DBS lead

06

What researchers measure

Primary outcomes

  1. Tolerability of patterned DBS

    The primary endpoint of this study is the proportion of participants who are able to tolerate patterned DBS (pDBS) for the full two-week intervention period. Tolerability is defined as the ability to remain on the assigned pDBS setting without reverting to an alternative DBS configuration.

    Time frame: From enrollment to the end of novel waveform trial period at 2 weeks

Secondary outcomes

  1. Change in motor symptom severity

    A comparison of the modified MDS-UPDRS between conventional and patterned waveform based on a video assessment

    Time frame: From enrollment to the end of study period at 4 weeks

  2. Change in quality of life

    A comparison of quality of life metrics through the Parkinson's Disease Questionnaire (PDQ-39) between conventional and patterned DBS

    Time frame: From enrollment to the end of the study period at 4 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Horn MA, Gulberti A, Gulke E, Buhmann C, Gerloff C, Moll CKE, Hamel W, Volkmann J, Potter-Nerger M. A New Stimulation Mode for Deep Brain Stimulation in Parkinson's Disease: Theta Burst Stimulation. Mov Disord. 2020 Aug;35(8):1471-1475. doi: 10.1002/mds.28083. Epub 2020 May 1. PubMed 32357269 ↗
  • Wong JK, Hu W, Barmore R, Lopes J, Moore K, Legacy J, Tahafchi P, Jackson Z, Judy JW, Raike RS, Wang A, Tsuboi T, Okun MS, Almeida L. Safety and Tolerability of Burst-Cycling Deep Brain Stimulation for Freezing of Gait in Parkinson's Disease. Front Hum Neurosci. 2021 Apr 26;15:651168. doi: 10.3389/fnhum.2021.651168. eCollection 2021. PubMed 33981207 ↗
  • Akbar U, Raike RS, Hack N, Hess CW, Skinner J, Martinez-Ramirez D, DeJesus S, Okun MS. Randomized, Blinded Pilot Testing of Nonconventional Stimulation Patterns and Shapes in Parkinson's Disease and Essential Tremor: Evidence for Further Evaluating Narrow and Biphasic Pulses. Neuromodulation. 2016 Jun;19(4):343-56. doi: 10.1111/ner.12397. Epub 2016 Mar 22. PubMed 27000764 ↗

Individual participant data

Plan to share: Yes — De-identified primary and secondary outcome data

Supporting information: Study protocol

Time frame: Data will be shared upon publication

Access criteria: Data will be shared as part of scientific publication

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Mar 2028, 21 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 21 months is below that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2026
First posted
Feb 13, 2026
StartActual
May 6, 2026
Primary completionEst.
Mar 1, 2028
CompletionEst.
Mar 1, 2028
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07410598
Responsible party
Sponsor
First posted
Feb 13, 2026
Start date
May 6, 2026
Primary completion
Mar 1, 2028 (estimated)
Completion
Mar 1, 2028 (estimated)
Last update
Jul 6, 2026

Study contacts

Joshua Wong, MD
Contact
joshua.wong@neurology.ufl.edu
352-294-5400

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion